

**CURRICULUM VITAE  
OREGON HEALTH & SCIENCE UNIVERSITY**

**NAME** Susan U Lattimore

**DATE** 4/26/2021

**PRESENT POSITION AND ADDRESS**

<b>Academic Rank:</b>	Instructor
<b>Department/Division:</b>	The Hemophilia Center, Institute on Development and Disability
<b>Professional Address:</b>	707 SW Gaines St Portland, OR 97239
<b>E-Mail Address:</b>	lattimor@ohsu.edu

**II. EDUCATION**

**Undergraduate and Graduate (Include Year, Degree, and Institution):**

1994 BS Nursing  
University of Pennsylvania  
Philadelphia, PA  
2018 GC Public Health  
Oregon Health & Science University  
Portland, OR

**Licenses (Include State, Date, Status, Number, and Renewal Date):**

2010-present Registered Nurse License – State of Oregon 201042518RN – 2/28/2022  
2005-2011 Registered Nurse License – State of Tennessee  
2001-2006 Registered Nurse License – State of Georgia  
1994-2001 Registered Nurse License – State of Pennsylvania

**III. PROFESSIONAL EXPERIENCE**

**Academic (Include Year, Position, and Institution):**

2016-present Instructor  
Oregon Health & Science University  
Portland, OR

**Administrative (Include Year, Position, and Institution):**

2017-present Associate Director, The Hemophilia Center  
Institute on Development and Disability  
Oregon Health & Science University  
2019-present Regional Director – Mountain States Region  
Regional Hemophilia Network  
Maternal Child Health Bureau HRSA  
2016-2019 Regional Coordinator – Mountain States Hemophilia Network  
Regional Hemophilia Network  
Maternal Child Health Bureau HRSA  
2015-2017 Research Director, The Hemophilia Center

Institute on Development and Disability  
Oregon Health & Science University

**Hospital/Clinical Appointments:**

2013-2016 Senior Research Nurse, The Hemophilia Center  
Oregon Health & Science University  
Portland, Oregon

2010-2013 Senior Research Nurse, Pediatric Clinical Research Office  
Oregon Health & Science University  
Portland, Oregon

2005-2010 Research Nurse Specialist III, Division of Trauma and Surgical Critical Care  
Vanderbilt University Medical Center  
Nashville, Tennessee

2001-2005 Charge Nurse, Perioperative Services  
Memorial Health University Medical Center  
Savannah, Georgia

2001-2004 Nurse Researcher, Section on Stroke Diagnostics and Therapeutics  
National Institute of Neurological Disorders and Stroke, National Institutes of Health  
Bethesda, Maryland

1999-2001 Program Coordinator / Nurse Researcher, Section on Stroke Diagnostics and  
Therapeutics  
National Institute of Neurological Disorders and Stroke, National Institutes of Health  
Bethesda, Maryland

1997-1999 Research Program Coordinator, Department of Neurosciences  
University of Pennsylvania Medical Center  
Philadelphia, Pennsylvania

1996-1997 Charge Nurse, Neuroscience Acute Care Unit  
University of Pennsylvania Medical Center  
Philadelphia, Pennsylvania

1994-1996 Staff Nurse, Neuroscience Acute Care Unit  
University of Pennsylvania Medical Center  
Philadelphia, Pennsylvania

**IV. SCHOLARSHIP**

**Area(s) of Research/Scholarly Interest:**

Access to Care, Health Disparities, Public Health

**Grants and Contracts:**

Federal (Include Title, Source, PI, Amount Period, and % Effort)

*Current*

Title: Hemophilia Treatment Centers (SPRANS) Source: Health Resources and Service Administration (H30MC24049), Amount: \$1,500,000 Role: Regional Director; PI: Susan Lattimore. % Effort: Funded FTE 0.26 Timeframe: 11/1/2019 – 5/31/2022

Title: Community Counts: Public Health Surveillance for Bleeding Disorders Source: Centers for Disease Control and Prevention via American Thrombosis and Hemostasis Network (NU27DD000020-01-00), Amount: \$1,513,645 Role: Regional Director; PI: Susan Lattimore. % Effort: Funded FTE 0.21 Timeframe: 9/30/2021 – 9/29/2025

*Completed*

Title: Hemophilia Treatment Centers (SPRANS) Source: Health Resources and Service Administration (H30MC24049), Amount: \$2,000,000 Role: Regional Coordinator; PI: Michael Recht. % Effort: Funded FTE 0.25 Timeframe: 6/1/2016 – 10/31/2019

Title: Community Counts: Public Health Surveillance for Bleeding Disorders Source: Centers for Disease Control and Prevention via American Thrombosis and Hemostasis Network (1U27DD001155-01), Amount: \$302,729 Role: Regional Director; PI: Susan Lattimore. % Effort: Funded FTE 0.21 Timeframe: 9/30/2019 – 9/29/2020

Other Support (Include Title, Source, PI, Amount Period, and % Effort)

Current

Title: ATHN 7: A natural history cohort study of the safety, effectiveness and practice of treatment for people with hemophilia. Source: American Thrombosis and Hemostasis Network, Amount: \$73,900 PI: Susan Lattimore. % Effort: Funded FTE 0.05 Timeframe: 1/1/2019 – 5/31/2024

**Publications/Creative Work:**

Peer-reviewed

Croteau SE, Wheeler AP, Khan O, Haley KM, Borst AJ, **Lattimore S**, Yeung, CT, Iorio A. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Res Pract Thromb Haemost 2020; 4(2):326-333.

Von Drygalski A, Giermasz A, Castaman G, Key NS, **Lattimore S**, Leebeek FWG, Miesbach W, Recht M, Long A, Rug R, Sawyer EK, Pipe SW. Etranocogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv 2019; 3(21):3241-3247

Rocheleau AD, Khader A, Ngo ATP, Boehnlein C, McDavitt C, **Lattimore S**, Recht M, McCarty OJT, Haley KM. Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. Pediatr Res 2018; 83(3):693-701

Baker-Groberg SM, **Lattimore S**, Recht M, McCarty OJT, Haley KM. Assessment of neonatal platelet adhesion, activation, and aggregation. J Thromb Haemost 2016; 14(4):815-27

Kang DW, **Lattimore SU**, Latour LL, Warach S. Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch Neurol 2006; 63(12):1730-3

Merino JG, **Lattimore SU**, Warach S. Telephone assessment of stroke outcome is reliable. Stroke 2005; 36(2):232-3

**Lattimore SU**, Chalela J, Davis L, DeGraba T, Exxeddine M, Haymore J, Nyquist P, Baird AE, Hallenbeck J, Warach S. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: The NINDS Suburban Hospital stroke center experience. Stroke 2003; 34(6):e55-7

Warach S, **Unipan S**, Olan WJ. Routine screening for IV tPA therapy less than 3 hours with MRI: initial clinical experience. Stroke 2000; 32:371.

Conroy MB, **Unipan S**, Kimmel SE, Kasner SE. Helicopter transfer offers a potential benefit to patients with acute stroke. Stroke 1999; 30(12):2580-4

Peer-Reviewed Electronic Publications

Roberts JC, **Lattimore S**, Recht M, Jackson S, Gue D, Squire S, Robinson KS, Price V, Denne M, Richardson S, Rockwood K. Goal attainment scaling for haemophilia (GAS-Hem): testing the feasibility of a new patient-centric outcome measure in people with haemophilia. Haemophilia 2018; 24(4):e199-e206

Peer-Reviewed Abstracts

Von Drygalski A, Giermasz A, Cataman G, Key NS, **Lattimore SU**, Leebeek FW, Miesbach WA, Recht M, Gomez E, Gut R, Pipe SW. Etranocogene dezaparvovec (AAV5-Padua hFIX variant), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia B: Two year data from a Phase 2b trial. Oral presentation. American Society of Hematology Annual Conference. Virtual. December 2020.

Journeycake JM, Recht M, Guelcher C, Neufeld EJ, Ragni MV, Sidonio RF, Takemoto C, Tarantino MD, Cheng D, **Lattimore SU**, Caicedo J, Denne M. Dosing, patient satisfaction and other patient-reported outcomes after switching to rurioctocog alfa pegol in Athn 2: a longitudinal, observational study of previously treated hemophilia patients switching coagulation replacement factor products. Poster presentation. American Society of Hematology Annual Conference. Virtual. December 2020.

Pipe SW, Recht M, Key NS, Leebeek FW, Castaman G, **Lattimore SU**, van der Valk P, Peerlinck K, Coppens V, O'Connell N, Pasi J, Kapmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons RS, Visweshwar N, Crary S, Kazmi R, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Baima N, Gut R, Miesbach WA. First data from the Phase 3 HOPE-B gene therapy trial: efficacy and safety of Etranacogene dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in adults with severe or moderate-severe hemophilia B treated irrespective of pre-existing anti-capcid neutralizing antibodies. Late breaking abstract session. American Society of Hematology Annual Conference. Virtual. December 2020.

**Lattimore SU**, Cox A, Haley KM, Hofstetter MT, Smith K. Does distance to hemophilia treatment center impact use of hemophilia treatment services? Poster presentation. Thrombosis and Hemostasis Society of North America Conference. Virtual. October 2020

Hofstetter M, Smith K, **Lattimore SU**. Engaging patients and families at emicizumab initiation. Poster presentation. Thrombosis and Hemostasis Society of North America Conference. Virtual. October 2020

**Lattimore SU**, Wagner D, Harris M, Haley K, Recht M, Stang E, Spiro K. Socially Vulnerable Youth with Bleeding Disorders: Piloting Novel Interventions in Children's Healthcare (NICH). Oral presentation. Thrombosis and Hemostasis Society of North America Conference. Virtual. October 2020

Baker J, **Lattimore S**. Patient satisfaction with hemophilia treatment centers: difference between milds and severes from the 2<sup>nd</sup> national US HTC patient satisfaction survey. Poster presentation. Thrombosis and Hemostasis Society of North America Conference. Virtual. October 2020

**Lattimore SU**, Hofstetter MT. Patient and family engagement during treatment change to emicizumab at a hemophilia treatment center. Poster. American Society of Hematology Annual Conference. December 2019.

Pipe S, Giernasz A, Castaman G, Key NS, **Lattimore SU**, Leebeek FWG, Miesbach W, Recht M, Gomez E, Long A, Gut R, von Drygalski A. One year data from a phase 2b trial of AMT-061 (AAV5-Padua hFIX variant), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia b. American Society of Hematology 2019

Sidonio RF, Cheng D, Guelcher C, Journeycake JM, **Lattimore SU**, Taekmoto C, Tarantino MD, Watson C, Neufeld EJ, Fedor C. Lack of inhibitor development in the American Thrombosis and Hemostasis Network (ATHN)-2 factor switching study: preliminary report of primary outcome. American Society of Hematology 2019

Long A, Von Drygalski A, Giermasz A, Castaman G, Key NS, **Lattimore S**, Leebeek FWG, Miesbach W, Recht M, Gomez E, Gut R, Pipe SW. Interim results from a phase 2b trial of AMT-061 (AAV5-Padua hFIX variant), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia b. World Hemophilia Foundation Global Forum 2019

Pipe SW, Giermasz A, Castaman G, Key NS, **Lattimore S**, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Von Drygalski A. AMT-061 (AAV5-Padua hFIX variant) an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia b: Follow-up up to 9 months in a phase 2b trial. National Hemophilia Foundation 2019.

Baker J, Shearer R, Ashton M, **Lattimore S**. Patient satisfaction with US hemophilia treatment centers: teen transition into adult care. National Hemophilia Foundation 2019

Von Drygalski A, Giernasz A, Castaman G, Key NS, **Lattimore S**, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Pipe SW. A single infusion of AMT-061 is safe and effective in adults with hemophilia b: Interim results from dose-confirmation phase 2b trial. Hemostasis and Thrombosis Research Society 2019.

**Lattimore SU**, Riske B, Ashton M, Shearer R, Baker J. Patient satisfaction with US hemophilia treatment centers: national trends 2014 and 2017. Hemostasis and Thrombosis Research Society 2019.

**Lattimore SU**, Castaman G, Key NS, Leebeek F, Miesbach W, Recht M, Long A, Gut R, Giernasz A, Pipe S. HOPE-B: Study design of a phase III trial of an investigational gene therapy AMT-061 in adults with severe or moderately severe hemophilia B. Hemostasis and Thrombosis Research Society 2019.

Olson D, Durben N, **Lattimore S**, Glenzer M, O'Connell M. The effect of bleeding disorder characteristics on patient-perceived challenges and management strategies. National Hemophilia Foundation 2019.

Goldscheitter G, **Lattimore S**, Taylor JA. Hemophilia associated bone pathology impacts quality of life. European Hematology Association 2019.

Goldscheitter G, **Lattimore S**, Taylor JA. Decreased skeletal health negatively impacts quality of life for people with hemophilia. American Society of Hematology 2018.

Konkle B, Recht M, Moore M, **Lattimore S**, Schwartz E, Ito D, Epstein J, Leony Lasso I, Richardson S. SPACE (Study of prophylaxis activity and effectiveness): An interim descriptive analysis of patient activity levels and participation. National Hemophilia Foundation annual 2017.

#### **Invited Lectures, Conference Presentations or Professorships:**

##### International and National

1. Lattimore S. Goal attainment scaling and motivational interviewing in hemophilia. Panel presenter: American Thrombosis and Hemostasis Network Data Summit, October, 2019, Chicago IL
2. Lattimore S. The Hemophilia Treatment Center Network. Plenary speaker: American Thrombosis and Hemostasis Network Data Summit, Oct 2019, Chicago, IL
3. Lattimore S. The role of the US regional hemophilia network. Plenary speaker: Hemophilia Alliance Annual Meeting, Sep 2019, Portland, OR
4. Lattimore S. Entering SPACE: patient activity levels and participation in hemophilia A. Plenary speaker: National Hemophilia Foundation Annual Meeting, Aug 2017, Chicago, IL
5. Unipan S. The impact of establishing a stroke center at a community hospital on the use of thrombolytic therapy: the NINDS-Suburban Hospital Stroke Center experience. Plenary speaker: American Heart Association International Stroke Conference, Aug 2000, Fort Lauderdale, FL

##### Regional and Local

1. Lattimore S. Future states: To bleed or not to bleed. Invited speaker: Hemophilia Foundation of Oregon Annual Meeting, Sep 2019, Portland, OR
2. Lattimore S. What's research got to do with it? Invited speaker: Hemophilia Foundation of Oregon Women's Conference, Nov 2017, Vancouver, WA.
3. Lattimore S. Goooooooooaaallllllllll! Goal setting and motivational interviewing in patient care. OHSU Pediatric Hematology/Oncology Grand Rounds, 2017, Portland, OR.

## V. SERVICE

### **Membership in Professional Societies:**

Member, Society of Clinical Research Associates – 1996-present

Member, Hemophilia and Thrombosis Research Society – 2017-present

Member, Foundation for Women and Girls with Blood Disorders – 2018-present

### **Committees:**

#### National

2015-present US Hemophilia Treatment Center Network Patient Satisfaction Survey Steering Committee.

2017-2020 National Hemophilia Program Coordinating Center, Quality Improvement Committee

2018-2019 National Institutes of Health, State of the Science FVIII Inhibitor Development Working Group Member

2017-2020 National Hemophilia Program Coordinating Center, Steering Committee, **Co-Chair**

1999-2000 Nation's Capital Area Stroke Council Member, American Heart Association

1999-2001 National Stroke Task Force, American Heart Association

#### Regional/Local

1997-1999 Philadelphia Stroke Council, Co-Chair

### **Community Service:**

2015-present Assistant Coach, Oregon Youth Soccer Association (Youth Rec / High School Co-Ed)

2018-present Friends of Cleveland Band Board Member

2021-present COVID-19 Volunteer Vaccinator, OHSU Vaccine Equity Committee

2015-2016 Sellwood Middle School Foundation

2012-2015 Llewellyn Elementary Foundation